MTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

Annals of the New York Academy of Sciences

Volumn 1346, Issue 1, 2015, Pages 33-44

  Perl, Andras ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Autoimmunity; Autophagy; Biomarker; Glutathione; Glycolysis; Hypoxia; Inflammation; Keloid disease; Kynurenine; Metabolism; Mitochondria; MTOR; Oxidative stress; Pathogenesis; Pentose phosphate pathway; Rapamycin; Sirolimus; Systemic lupus erythematosus; T cell activation; Treatment

Indexed keywords

BIOLOGICAL MARKER; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADAPTIVE IMMUNITY; AGING; ARTICLE; AUTOIMMUNE DISEASE; AUTOPHAGY; CARBOHYDRATE METABOLISM; CELL HYPOXIA; CELL PROLIFERATION; CELL SPECIFICITY; CELL SURVIVAL; DIABETES MELLITUS; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; GRAFT REJECTION; HUMAN; INNATE IMMUNITY; LIFESPAN; LIPOGENESIS; LYMPHOCYTE PROLIFERATION; NEOPLASM; OBESITY; OXIDATIVE STRESS; PERSONALIZED MEDICINE; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; DRUG EFFECTS; METABOLISM; NEOPLASMS; PROCEDURES;

AGING; ANIMALS; AUTOIMMUNE DISEASES; BIOMARKERS; HUMANS; NEOPLASMS; OBESITY; PRECISION MEDICINE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84949097466     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12756     Document Type: Article

References (140)

1. Vezina, C., A. Kudelski & S.N. Sehgal. 1975. Rapamycin (AY 22989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28: 721-726.
2. Sehgal, S.N. & C.C. Bansback. 1993. Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann. N.Y. Acad. Sci. 685: 58-67.
3. Warner, L.M., L.M. Adams & S.N. Sehgal. 1994. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arth. Rheum. 37: 289-297.
4. Fernandez, D., E. Bonilla, N. Mirza, et al. 2006. Rapamycin reduces disease activity and normalizes T-cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2983-2988.
5. Collier, D.S.J., R. Calne, S. Thiru, et al. 1990. Rapamycin in experimental renal allografts in dogs and pigs. Transplant. Proc. 22: 1674-1675.
6. Calne, R.Y., S. Lim, A. Samaan, et al. 1989. Rapamycin for immunosuppression in organ allografting. Lancet 334: 227.
7. Sindhi, R., M.F. LaVia, E. Paulling, et al. 2000. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation 69: 432-436.
8. Aghdasi, B., K. Ye, A. Resnick, et al. 2001. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc. Natl. Acad. Sci. USA 98: 2425-2430.
9. Dolinski, K., S. Muir, M. Cardenas & J. Heitman. 1997. All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 94: 13093-13098.
10. Sabatini, D.M., H. Erdjument-Bromage, M. Lui, et al. 1994. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78: 35-43.
11. Laplante, M. & D.M. Sabatini. 2013. Regulation of mTORC1 and its impact on gene expression at a glance. J. Cell Sci. 126: 1713-1719.
12. Bar-Peled, L., L. Chantranupong, A.D. Cherniack, et al. 2013. A tumor suppressor complex with GAP activity for the rag GTPases that signal amino acid sufficiency to mTORC1. Science 340: 1100-1106.
13. Mihaylova, M.M. & R.J. Shaw. 2011. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13: 1016-1023.
14. Gingras, A.C., S.P. Gygi, B. Raught, et al. 1999. Regulation of 4E-BP1 phosphorylation: a novel two step mechanism. Genes Dev. 13: 1422-1437.
15. Fonseca, B.D., G.H. Diering, M.A. Bidinosti, et al. 2012. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 287: 17530-17545.
16. Lamming, D.W., L. Ye, P. Katajisto, et al. 2012. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638-1643.
17. Guertin, D.A., D.M. Stevens, C.C. Thoreen, et al. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC[alpha], but Not S6K1. Dev. Cell 11: 859-871.
18. Xu, K., P. Liu & W. Wei. 2014. MTOR signaling in tumorigenesis. Biochim. Biophys. Acta 1846: 638-654.
19. Liu, P., W. Gan, H. Inuzuka, et al. 2013. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat. Cell Biol. 15: 1340-1350.
20. Fernandez, D.R., T. Telarico, E. Bonilla, et al. 2009. Activation of mTOR controls the loss of TCR in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J. Immunol. 182: 2063-2073.
21. Lai, Z.-W., R. Hanczko, E. Bonilla, et al. 2012. N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. Arthritis Rheum. 64: 2937-2946.
22. + DN T cells and contracts Tregs in SLE. J. Immunol. 192: 4134-4144.
23. Lai, Z.-W., R. Borsuk, A. Shadakshari, et al. 2013. mTOR activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus eryhthematosus. J. Immunol. 191: 2236-2246.
24. Carbone, F., V. De Rosa, P.B. Carrieri, et al. 2014. Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat. Med. 20: 69-74.
25. Esposito, M., F. Ruffini, M. Bellone, et al. 2010. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J. Neuroimmunol. 220: 52-63.
26. Delgoffe, G.M., K.N. Pollizzi, A.T. Waickman, et al. 2011. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12: 295-304.
27. McCormack, F.X., Y. Inoue, J. Moss, et al. 2011. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med. 364: 1595-1606.
28. Julich, K. & M. Sahin. 2014. Mechanism-based treatment in tuberous sclerosis complex. Ped. Neurol. 50: 290-296.
29. Brewster, A.L., J.N. Lugo, V.V. Patil, et al. 2013. Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage. PLoS ONE 8: e57808.
30. +/- mouse model of tuberous sclerosis. Nat. Med. 14: 843-848.
31. Waltereit, R., H. Welzl, J. Dichgans, et al. 2006. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J. Neurochem. 96: 407-413.
32. Huynh, T.N., E. Santini & E. Klann. 2014. Requirement of mammalian target of rapamycin complex 1 downstream effectors in cued fear memory reconsolidation and its persistence. J. Neurosci. 34: 9034-9039.
33. Gkikas, I., D. Petratou & N. Tavernarakis. 2014. Longevity pathways and memory aging. Front. Genet. 5: 155.
34. Franke, T.F., D.R. Kaplan & L.C. Cantley. 1997. PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-437.
35. Yoshida, S., S. Hong, T. Suzuki, et al. 2011. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J. Biol. Chem. 286: 32651-32660.
36. Sarbassov, d.D. & D.M. Sabatini. 2005. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J. Biol. Chem. 280: 39505-39509.
37. Desai, B.N., B.R. Myers & S.L. Schreiber. 2002. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. USA 99: 4319-4324.
38. Chauvin, C., V. Koka, A. Nouschi, et al. 2014. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 33: 474-483.
39. Jung, H., C.G. Gkogkas, N. Sonenberg & C.E. Holt. 2014. Remote control of gene function by local translation. Cell 157: 26-40.
40. Dowling, R.J.O., I. Topisirovic, B.D. Fonseca & N. Sonenberg. 2010. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta 1804: 433-439.
41. Lekmine, F., S. Uddin, A. Sassano, et al. 2003. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J. Biol. Chem. 278: 27772-27780.
42. Mieulet, V., M. Roceri, C. Espeillac, et al. 2007. S6 kinase inactivation impairs growth and translational target phosphorylation in muscle cells maintaining proper regulation of protein turnover. Am. J. Physiol. Cell Physiol. 293: C712-C722.
43. Duvel, K., J.L. Yecies, S. Menon, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39: 171-183.
44. Semenza, G.L. 2013. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123: 3664-3671.
45. Liu, G., Y. Bi, B. Shen, et al. 2014. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1-α dependent glycolysis. Cancer Res. 74: 727-737.
46. Ben-Sahra, I., J.J. Howell, J.M. Asara & B.D. Manning. 2013. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339: 1323-1328.
47. Nazio, F., F. Strappazzon, M. Antonioli, et al. 2013. MTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat. Cell. Biol. 15: 406-416.
48. Zinzalla, V., D. Stracka, W. Oppliger & M.N. Hall. 2011. Activation of mTORC2 by association with the ribosome. Cell 144: 757-768.
49. Dai, N., J. Christiansen, F.C. Nielsen & J. Avruch. 2013. mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts. Genes Dev. 27: 301-312.
50. Hagiwara, A., M. Cornu, N. Cybulski, et al. 2012. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 15: 725-738.
51. Zhang, C., D.E. Cooper, T.J. Grevengoed, et al. 2014. Glycerol-3-phosphate acyltransferase-4-deficient mice are protected from diet-induced insulin resistance by the enhanced association of mTOR and rictor. Am. J. Physiol. Endocrin. Metab. 307: E305-E315.
52. Ramakrishnan, G., G. Davaakhuu, L. Kaplun, et al. 2014. Sirt2 deacetylase is a novel AKT Binding partner critical for AKT activation by insulin. J. Biol. Chem. 289: 6054-6066.
53. Sato, M., N. Dehvari, A.I. Oberg, et al. 2014. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes 63: 4115-4129.
54. Khamzina, L., A. Veilleux, S. Bergeron & A. Marette. 2005. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 146: 1473-1481.
55. Krebs, M., B. Brunmair, A. Brehm, et al. 2007. The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 56: 1600-1607.
56. Yeh, W.C., B.E. Bierer & S.L. McKnight. 1995. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc. Natl. Acad. Sci. USA 92: 11086-11090.
57. Bell, A., L. Grunder & A. Sorisky. 2000. Rapamycin inhibits human adipocyte differentiation in primary culture. Obesity Res. 8: 249-254.
58. Chang, G.R., Y.S. Chiu, Y.Y. Wu, et al. 2009. Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. J. Pharmacol. Sci. 109: 496-503.
59. Chang, G.R., Y.Y. Wu, Y.S. Chiu, et al. 2009. Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Bas. Clin. Pharmacol. Toxicol. 105: 188-198.
60. Houde, V.P., S. Brule, W.T. Festuccia, et al. 2010. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59: 1338-1348.
61. Fraenkel, M., M. Ketzinel-Gilad, Y. Ariav, et al. 2008. mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57: 945-957.
62. Fang, Y., R. Westbrook, C. Hill, et al. 2013. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab. 17: 456-462.
63. Caro-Maldonado, A., V.A. Gerriets & J.C. Rathmell. 2012. Matched and mismatched metabolic fuels in lymphocyte function. Semin. Immunol. 24: 405-413.
64. Wang, R., C.P. Dillon, L.Z. Shi, et al. 2011. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35: 871-882.
65. Araki, K., A.P. Turner, V.O. Shaffer, et al. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108-112.
66. Fernandez, D.R. & A. Perl. 2010. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov. Med. 9: 173-178.
67. Moulton, V.R. & G.C. Tsokos. 2011. Abnormalities of T cell signaling in systemic lupus erythematosus. Arth. Res. Ther. 13: 207.
68. Tomasoni, R., V. Basso, K. Pilipow, et al. 2011. Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation. Eur. J. Immunol. 41: 2086-2096.
69. Shrestha, S., K. Yang, C. Guy, et al. 2015. Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat. Immunol. 16: 178-187.
70. Ray, J.P. & J. Craft. 2015. PTENtiating autoimmunity through Treg cell deregulation. Nat. Immunol. 16: 139-140.
71. Sieling, P.A., S.A. Porcelli, B.T. Duong, et al. 2000. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J. Immunol. 165: 5338-5344.
72. + T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 143: 103-112.
73. Tan, E.M., A.S. Cohen, J.F. Fries, et al. 1982. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arth. Rheum. 25: 1271-1277.
74. Hochberg, M.C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arth. Rheum. 40: 1725.
75. Petri, M., A M. Orbai, G.S. Alarcón, et al. 2012. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arth. Rheum. 64: 2677-2686.
76. Miyakis, S., M.D. Lockshin, T. Atsumi, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).[see comment]. [136 refs]. J. Thromb. Haemost. 4: 295-306.
77. Canaud, G., F. Bienaimé, F. Tabarin, et al. 2014. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371: 303-312.
78. Giannakopoulos, B. & S.A. Krilis. 2013. The pathogenesis of the antiphospholipid syndrome. N. Engl. J. Med. 368: 1033-1044.
79. Tsokos, G.C. 2011. Systemic lupus erythematosus. N. Engl. J. Med. 365: 2110-2121.
80. Doherty, E., Z. Oaks & A. Perl. 2014. Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. Antiox. Redox Signal. 21: 56-65.
81. + T cell metabolism reverses lupus. Sci. Transl. Med. 7: 274ra18.
82. Perl, A. 2013. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat. Rev. Rheumatol. 9: 674-686.
83. Chi, H. 2012. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 12: 325-338.
84. Barbi, J., D. Pardoll & F. Pan. 2013. Metabolic control of the Treg/Th17 axis. Immunol. Rev. 252: 52-77.
85. Dang, E.V., J. Barbi, H.Y. Yang, et al. 2011. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell 146: 772-784.
86. Bell, E.L., T.A. Klimova, J. Eisenbart, et al. 2007. Mitochondrial reactive oxygen species trigger hypoxia-inducible factor-dependent extension of the replicative life span during hypoxia. Mol. Cell. Biol. 27: 5737-5745.
87. Toschi, A., E. Lee, N. Gadir, et al. 2008. Differential dependence of hypoxia-inducible factors 1-α and 2-α on mTORC1 and mTORC2. J. Biol. Chem. 283: 34495-34499.
88. Perl, A., R. Hanczko, Z.-W. Lai, et al. 2015. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics. In press. http://link.springer.com/article/10.1007/s11306-015-0772-0.
89. Breton, J., N. Avanzi, S. Magagnin, et al. 2000. Functional characterization and mechanism of action of recombinant human kynurenine 3-hydroxylase. Eur. J. Biochem. 267: 1092-1099.
90. Hanczko, R., D. Fernandez, E. Doherty, et al. 2009. Prevention of hepatocarcinogenesis and acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J. Clin. Invest. 119: 1546-1557.
91. Perl, A., R. Hanczko, T. Telarico, et al. 2011. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol. Med. 7: 395-403.
92. Singh, N., M. Birkenbach, T. Caza, et al. 2013. Tuberous sclerosis and fulminant lupus in a young woman. J. Clin. Rheumatol. 19: 134-137.
93. Julien, L.A., A. Carriere, J. Moreau & P.P. Roux. 2010. mTORC1-activated S6K1 phosphorylates rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 30: 908-921.
94. Schenone, S., C. Brullo, F. Musumeci, et al. 2011. ATP-competitive inhibitors of mTOR: An update. Curr. Med. Chem. 18: 2995-3014.
95. Kwiatkowski, D.J. 2003. Tuberous sclerosis: from tubers to mTOR. Ann. Hum. Genet. 67: 87-96.
96. Li, C., P.S. Lee, Y. Sun, et al. 2014. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J. Exp. Med. 211: 15-28.
97. Feng, Z., H. Zhang, A.J. Levine & S. Jin. 2005. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 102: 8204-8209.
98. Vogelstein, B., D. Lane & A.J. Levine. 2000. Surfing the p53 network. Nature 408: 307-310.
99. Feng, Z., W. Hu, E. de Stanchina, et al. 2007. The regulation of AMPKβ1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67: 3043-3053.
100. Sun, Q., X. Chen, J. Ma, et al. 2011. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 108: 4129-4134.
101. Warburg, O. 1956. On the origin of cancer cells. Science 123: 309-314.
102. Guertin, D.A., D.M. Stevens, M. Saitoh, et al. 2009. The mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15: 148-159.
103. Qi, W.X., Y.J. Huang, Y. Yao, et al. 2013. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis. PLoS ONE 8: e65166.
104. Thoreen, C.C., S.A. Kang, J.W. Chang, et al. 2009. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant Functions of mTORC1. J. Biol. Chem. 284: 8023-8032.
105. Chiarini, F., C. Evangelisti, J.A. McCubrey & A.M. Martelli. 2015. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharm. Sci. 36: 124-135.
106. Chiarini, F., C. Grimaldi, F. Ricci, et al. 2010. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res. 70: 8097-8107.
107. Markman, B., J. Tabernero, I. Krop, et al. 2012. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 23: 2399-2408.
108. Harrison, D.E., R. Strong, Z.D. Sharp, et al. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392-395.
109. Miller, R.A., D.E. Harrison, C.M. Astle, et al. 2014. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13: 468-477
110. Ye, L., A.L. Widlund, C.A. Sims, et al. 2013. Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance. Aging 5: 539-550.
111. Chen, C., Y. Liu, Y. Liu & P. Zheng. 2009. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci. Signal. 2: ra75.
112. Caza, T.N., D. Fernandez, G. Talaber, et al. 2014. HRES-1/RAB4-mediated depletion of DRP1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann. Rheum. Dis. 73: 1887-1897.
113. Syed, F., H.J. Sanganee, A. Bahl & A. Bayat. 2013. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity. J. Invest. Dermatol. 133: 1340-1350.
114. Stefanini, G.G. & D.R. Holmes. 2013. Drug-eluting coronary-artery stents. N. Engl. J. Med. 368: 254-265.
115. Brattstrom, C., H. Wilczek, G. Tyden, et al. 1998. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65: 1272-1274.
116. Trager, J. & M.M. Ward. 2001. Mortality and causes of death in systemic lupus erythematosus. Curr. Opin. Rheumatol. 13: 345-351.
117. Lee, R., M. Margaritis, K.M. Channon & C. Antoniades. 2012. Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations. Curr. Med. Chem. 19: 2504-2520.
118. Tepel, M., M. van der Giet, M. Statz, et al. 2003. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 107: 992-995.
119. Franceschini, G., J.P. Werba, O. Safa, et al. 1993. Dose-related increase of HDL-cholesterol levels after N-acetylcysteine in man. Pharmacol. Res. 28: 213-218.
120. Kinscherf, R., K. Cafaltzis, F. Roder, et al. 2003. Cholesterol levels linked to abnormal plasma thiol concentrations and thiol/disulfide redox status in hyperlipidemic subjects. Free Rad. Biol. Med. 35: 1286-1292.
121. Ilowite, N.T., P. Samuel, E. Ginzler & M.S. Jacobson. 1988. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis. Rheum. 31: 859-863.
122. Lahita, R.G., E. Rivkin, I. Cavanagh & P. Romano. 1993. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 36: 1566-1574.
123. Formiga, F., J.F. Meco, X. Pinto, et al. 2001. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10: 359-363.
124. Svenungsson, E., K. Jensen-Urstad, M. Heimbürger, et al. 2001. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104: 1887-1893.
125. de Carvalho, J.F., E. Bonfa & E.F. Borba. 2008. Systemic lupus erythematosus and "lupus dyslipoproteinemia." Autoimmunity Rev. 7: 246-250.
126. Telles, R.W., C.C.D. Lanna, G.A. Ferreira & A.L. Ribeiro. 2010. Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus 19: 803-809.
127. Ardoin, S.P., L.E. Schanberg, C. Sandborg, et al. 2010. Laboratory markers of cardiovascular risk in pediatri SLE: the APPLE baseline cohort. Lupus 19: 1315-1325.
128. Srivastava, R., S. Yu, B.W. Parks, et al. 2011. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone old mice. Arthritis Rheum. 63: 201-211.
129. Parker, B., Y. Ahmad, J. Shelmerdine, et al. 2011. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 20: 1459-1465.
130. Volkers, M., M.H. Konstandin, S. Doroudgar, et al. 2013. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Circulation 128: 2132-2144.
131. Moschella, P.C., J. McKillop, D.L. Pleasant, et al. 2013. mTOR complex 2 mediates Akt phosphorylation that requires PKCε in adult cardiac muscle cells. Cell. Signal. 25: 1904-1912.
132. Peng, L., Y. Zhou, X. Ye & Q. Zhao. 2015. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer meta-analysis of clinical trials. Tumor Biol. 36: 643-654
133. Akeno, N., A.L. Miller, X. Ma & K.A. Wikenheiser-Brokamp. 2015. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene 34: 589-599.
134. Weigelt, B., P.H. Warne & J. Downward. 2011. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30: 3222-3233.
135. Sudhagar, S., S. Sathya & B.S. Lakshmi. 2011. Rapid non-genomic signalling by 17[beta]-oestradiol through c-Src involves mTOR-dependent expression of HIF-1[alpha] in breast cancer cells. Br. J. Cancer 105: 953-960.
136. + T cells. J. Exp. Med. 209: 2441-2453.
137. + T cell subsets and inflammation. J. Clin. Invest. 125: 194-207.
138. Sehgal, S.N. 2003. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35: S7-S14.
139. Dancey, J.E. 2006. Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. 5: 1065-1073.
140. Chresta, C.M., B.R. Davies, I. Hickson, et al. 2010. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70: 288-298.